- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Zhengye Biotechnology regains Nasdaq bid price compliance; shares down | 2 | Seeking Alpha | ||
| 22.07. | Zhengye Biotechnology Stock Plunges Following 322% Rally In Volatile Reversal | 18 | Benzinga.com | ||
| ZHENGYE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 21.07. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 21.07. | Morning Market Movers: Zhengye Biotechnology, Lisata Therapeutics, Meiwu Technology, Danaher Corporation See Big Swings | 1.165 | AFX News | WASHINGTON (dpa-AFX) - At 9:00 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 21.07. | Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity | 448 | GlobeNewswire (Europe) | Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 04.06. | Zhengye Biotechnology receives Nasdaq bid price deficiency notice | 2 | Investing.com | ||
| 04.06. | Zhengye Biotechnology Holding Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | 263 | GlobeNewswire (Europe) | Jilin, China, June 04, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 04.06. | Zhengye Biotechnology Holding Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.04. | Zhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial Results | 337 | PR Newswire | JILIN, China, April 28, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer... ► Artikel lesen | |
| 06.04. | Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure | 354 | GlobeNewswire (Europe) | Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
| 10.02. | Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders | 1.019 | GlobeNewswire (Europe) | Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 17,200 | -0,35 % | FDA Approves Viatris' RYZUMVI For Presbyopia Treatment | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.RYZUMVI... ► Artikel lesen | |
| SYNBIOTIC | 0,200 | -6,54 % | SYNBIOTIC SE: Zuvor aufgezeigte Risiken haben sich materialisiert; Rating und Kursziel under review | SYNBIOTIC hat angekündigt, einen Insolvenzantrag zu stellen, nachdem es dem Unternehmen angesichts anhaltend schwieriger Marktbedingungen nicht gelungen ist, eine ausreichende Finanzierung sicherzustellen.... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,843 | 0,00 % | Organigram Global Inc.: Organigram Global treibt die Integration der Sanity Group unter einer einheitlichen globalen Betriebsstruktur voran | Führung, operatives Geschäft und Marktentwicklung werden über eine globale Plattform aufeinander abgestimmt, die Kanada mit Deutschland und anderen wichtigen internationalen Märkten verbindet
Die... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 4,934 | +4,07 % | Tonix Pharmaceuticals stellt Phase-3-Daten zu Fibromyalgie-Präparat auf Fachkongress vor | ||
| ORAMED PHARMACEUTICALS | 3,745 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 8,960 | +1,13 % | Sellas falls as REGAL trial nears final analysis | ||
| OPKO HEALTH | 1,450 | -0,68 % | OPKO Health, Inc.: OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| XORTX THERAPEUTICS | 0,924 | -2,16 % | XORTX Therapeutics Inc.: XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO, Targeting USD$700M+ U.S. Gout Market Opportunity | CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative... ► Artikel lesen | |
| SOLIGENIX | 0,368 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 3,180 | 0,00 % | Opus Genetics appoints chief scientific officer, operations head | ||
| TALPHERA | 0,965 | +1,05 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,486 | +1,04 % | Savara Inc.: Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 | -- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases... ► Artikel lesen | |
| SCYNEXIS | 3,570 | +2,59 % | SCYNEXIS reports phase 1 results for IV antifungal SCY-247 | ||
| PROTHENA | 8,148 | +4,03 % | Prothena Corporation plc: Prothena to Report Third Quarter 2026 Financial Results on November 5 | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 3,320 | +2,00 % | Wave Life Sciences, Inc. - 10-Q, Quarterly Report |
Das Unternehmen ZHENGYE BIOTECHNOLOGY HOLDING LIMITED kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,70 % bei einem Aktienkurs von 1,440 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHENGYE BIOTECHNOLOGY HOLDING LIMITED finden Sie auf Wallstreet Online.